Soligenix CEO Provides Updates on HyBryte(TM) in Benzinga Interview
Soligenix Inc.'s CEO, Christopher J. Schaber, shares updates on the company's focus on developing treatments for rare diseases like HyBryte(TM) in an exclusive interview with Benzinga. Learn more about the latest advancements in biopharmaceutical research.
This news highlights the innovative work being done by Soligenix Inc. in the field of biopharmaceuticals, specifically in the development of treatments for rare diseases. The potential success of HyBryte(TM) could have a significant impact on patients suffering from cutaneous T-cell lymphoma and other inflammatory diseases.